The Difference Between Life and Living
Sancuso for Chemotherapy-Induced Nausea & Vomiting1
A convenient, 5-day patch for effective CINV prevention2, because every moment matters
Consistent Medication3
With Sancuso, your loved one gets steady relief the entire time the patch is worn (5-7 days), without the ups and downs of daily pills. This means continuous support, even on days when managing medication schedules feels overwhelming.
Non-Invasive Option
Sancuso allows patients to focus on their treatment with minimal disruption. Caregivers can feel confident knowing they are supporting their loved ones with a noninvasive option.
Clinical Evidence
Sancuso is backed by clinical research. Learn more about its proven efficacy throughout our website and in our prescribing information.4
Applying the Sancuso Patch: A Step-by-Step Guide
Simple application for CINV protection
Step 1
Remove the patch from the carton; tear the pouch open and remove the patch. Each pouch contains one Sancuso patch stuck into a rigid plastic film, and a separate clear protective liner.
Do not remove the Sancuso patch from the pouch until you are ready to use it.
Step 2
Remove the thin, clear protective liner to expose the printed side of the patch.
Step 3
Bend the patch in the middle and remove one half of the rigid plastic film. Be careful not to stick the patch to itself and avoid touching the sticky side of the patch.
Step 4
While holding the remaining half of the rigid plastic film, apply the patch to the skin. Remove the second half of the rigid plastic film and press the whole patch firmly in place with your fingers and smooth down. Press firmly, making sure it sticks well, especially around the edges.
Step 5
Wash your hands right away after applying the patch to remove any medicine that might have stuck to your fingers.
Step 6
Keep the patch in place for the duration of the chemotherapy. Remove the patch at least 1 day (24 hours) after chemotherapy is finished. The patch can be worn up to 7 days, depending on the number of days that your chemotherapy treatment lasts.
Do not reuse the Sancuso patch after you remove it. See instructions included with your Sancuso patch on how to remove and throw away after use.
Sancuso Guidance
- Be sure to keep the Sancuso patch inside the sealed pouch until you are ready to apply it
- Do not cut the patch
- Apply Sancuso a minimum of 24 hours to a maximum of 48 hours before your scheduled chemotherapy treatment
- Apply Sancuso to a clean, dry, nearly hairless area of skin on the outside of your upper arm. Do not put Sancuso on areas that have been treated with creams, oils, lotions, powders, or other skin care products that might keep the patch from sticking on your skin. Sancuso should not be placed on skin that is red, irritated, cut, or scraped
- If the patch doesn't stick well, you may use medical adhesive tape to keep the patch in place. Place tape on the edges of the patch. Do not completely cover the patch with tape, and do not wrap entirely around your arm
- If the patch comes more than halfway off or it becomes damaged, please contact your healthcare provider
- For our Patch Replacement Program, contact Patient Rx Solutions™ Customer Service Support Phone: 615-425-7642
Supporting Your Loved One During Chemotherapy
Small steps you can take to make a big difference
Encourage Open Communication
You can encourage open communication by asking about symptoms and side effects with care and reassurance. Open conversations help ensure the best possible care for your loved one.
How to Monitor Symptoms
Keep a daily log of nausea, side effects, and any changes in how your loved one feels. Share updates with their healthcare provider to ensure the best care.
Your Support Makes a Difference
Offer reassurance, listen without judgment, and remind them they're not alone. Your support makes a difference.
INDICATIONS AND USAGE
SANCUSO (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
WARNINGS AND PRECAUTIONS
PROGRESSIVE ILEUS AND GASTRIC DISTENTION: Sancuso may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of Sancuso in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
SEROTONIN SYNDROME: The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of sancuso and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Sancuso and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Sancuso is used concomitantly with other serotonergic drugs.
SKIN REACTIONS: In clinical trials with Sancuso, application site reactions were reported that were generally mild in intensity and did not lead to discontinuation of use. The incidence of reactions was comparable with placebo. If severe reactions, or a generalized skin reaction occur (e.g., allergic rash, including erythematous, macular, papular rash or pruritus), remove the Sancuso transdermal system.
INCREASED DRUG EXPOSURE WITH USE OF EXTERNAL HEAT SOURCES: Prolonged exposure to heat results in increasing plasma concentrations of granisetron during the period of heat exposure. Do not apply a heat pad or heat lamp over or in the vicinity of the Sancuso transdermal system and avoid extended exposure to heat.
PHOTOTOXICITY WITH ULTRAVIOLET LIGHT EXPOSURE: Granisetron may be affected by direct natural or artificial sunlight, including sunlamps. An in vitro study using Chinese hamster ovary cells suggests that granisetron has the potential for photogenotoxicity. To avoid a potential skin reaction, advise patients to cover the application site of the transdermal system with clothing if there is a risk of exposure to direct natural or artificial sunlight throughout the period of wear and for 10 days following its removal.
ADVERSE REACTIONS
The most common adverse reaction (≥ 5%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals, Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INDICATIONS AND USAGE
SANCUSO
- Sancuso [package insert]. Nashville, TN, Cumberland Pharmaceuticals Inc.; 2024.
- Boccia RV, Gordon LN, Clark G, Howell JD, Grun SM; on behalf of the Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy; a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617.
- Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179-185.
- Data on file, Cumberland Pharmaceuticals Inc. 2025.
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
